FDA may insist on KRAS tests for cancer patients
The US Food and Drug Administration is considering alterations to the labeling of certain cancer drugs to discourage their use in patients who are unlikely to benefit from them because of their genetic profile.
The FDA's Oncologic Drugs Advisory Committee is discussing whether US drug majors Eli Lilly and Bristol-Myers Squibb's Erbitux (cetuximab) and biotechnology firm Amgen's Vectibix (panitumumab) will have new labeling added that will suggest that colon cancer patients are screened for the KRAS gene mutation - which can counteract the efficacy of the treatments - before they are prescribed the drugs.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
| Headless Content Management with Blaze